DUBLIN, May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences.
Jefferies Healthcare Conference
Date/Time: Wednesday, June 7, 2023 at 10:00 a.m. EDT (3:00 p.m. BST)
Goldman Sachs 44th Annual Global Healthcare Conference
Date/Time: Monday, June 12, 2023 at 9:20 a.m. PDT (12:20 p.m. EDT/5:20 p.m. BST)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Bernard
Investor Relations
+1 781 873 2402
| Last Trade: | US$27.87 |
| Daily Change: | 0.48 1.75 |
| Daily Volume: | 2,189,144 |
| Market Cap: | US$4.600B |
September 08, 2025 July 29, 2025 June 02, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
